Claims

1. A method for assessing an increased risk for cardiovascular mortality in a pre-diabetic or diabetic subject, comprising:

(a) determining in a blood sample from said subject
(i) the amount of a first marker alpha-Glutathione-S-Transferase; and
(ii) optionally the amount of at least a further marker; and
(b) correlating that said subject is at increased risk for cardiovascular mortality when said amount is altered compared to a reference amount for the first marker and optionally to a reference amount for the further marker.

2. The method according to claim 1 wherein the amount of a further marker is determined.

3. The method according to claim 2 wherein said further marker is selected from the group consisting of Nt-pro BNP, Angiopoietin-2, Growth Differentiation Factor 15, Peroxiredoxin-4 YKL-40, Osteoprotegerin, Chromogranin A, and Insulin-like Growth Factor Binding Protein 2.

4. The method according to claims 1 or 2 wherein said further marker is:
Trefoil Factor 3, Macrophage-derived Chemokine, and alpha-2-Macroglobulin.

5. The method according to any one of the preceding claims wherein said further marker is Nt-pro BNP, Growth Differentiation Factor 15, Trefoil Factor 3, alpha-2-Macroglobulin, Macrophage-derived Chemokine, Angiopoietin-2, YKL-40, Peroxiredoxin-4 and Insulin-like Growth Factor Binding Protein 2.

6. The method according to any one of claims 1-3, wherein said further marker is Trefoil Factor 3, alpha-2-Macroglobulin, Macrophage-derived Chemokine, Apolipoprotein B, Selenoprotein P, Tenascin C, Hepatocyte Growth Factor Receptor,

Growth Differentiation Factor 15, Insulin-like Growth Factor Binding Protein 2, Angiopoietin 2, Nt-proBNP, YKL40, Osteoprotegerin and Chromogranin A.

7. The method according to any one of claims 1-3, wherein said further marker is Trefoil Factor 3, Macrophage-derived Chemokine, alpha-2-Macroglobulin, Selenoprotein P, Tenascin C, Growth Differentiation Factor 15, Insulin-like Growth Factor Binding Protein 2, Angiopoietin 2, Nt-proBNP, YKL40, and Chromogranin A.

8. The method according to any one of the preceding claims, wherein said further marker is Nt-pro BNP and Angiopoietin 2.

9. The method according to any one of the preceding claims, wherein the cardiovascular mortality is selected from fatal myocardial infarction, fatal stroke, and/or heart failure.

10. The method according to any one of the preceding claims wherein said increased risk for cardiovascular mortality is within the next 1-7 years.

11. The method according to any one of the preceding claims wherein:
(i) the subject has an age of at least 50 years; and/or
(ii) the subject had a previous cardiovascular disorder.

12. The method according to claim 9 wherein the subject:
(i) has an age of at least 50 years; and
(ii) had a previous cardiovascular disorder.

13. The method of claim 12, wherein the prediabetic or diabetic subject suffers from one or more of the risk factors comprising previous cardiovascular disorder, albuminuria, male, age of at least 55 years, elevated blood cholesterol level, smoker, and hypertension.

14. The method according to any one of the preceding claims wherein the blood sample is serum and/or plasma.